T. A. Zelniker, S. D. Wiviott, I. Raz, K. Im, E. L. Goodrich et al., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, The Lancet, vol.393, issue.10166, pp.31-39, 2019.

V. Perkovic, M. J. Jardine, B. Neal, S. Bompoint, H. J. Heerspink et al., Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, New England Journal of Medicine, vol.380, issue.24, pp.2295-2306, 2019.

B. Zinman, G. Meininger, B. M. Brenner, and K. W. Mahaffey, CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med, vol.380, pp.2295-2306, 2019.

K. Cowart and N. W. Carris, Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?, Expert Opinion on Pharmacotherapy, pp.1-3, 2020.

M. Packer, Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes, Diabetes Care, vol.41, issue.1, pp.11-13, 2017.

S. D. Wiviott, I. Raz, M. P. Bonaca, O. Mosenzon, E. T. Kato et al., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.380, issue.4, pp.347-357, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02543624

B. Zinman, C. Wanner, J. M. Lachin, D. Fitchett, E. Bluhmki et al., Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.22, pp.2117-2128, 2015.

R. H. Furtado, M. P. Bonaca, I. Raz, T. A. Zelniker, O. Mosenzon et al., Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction, Circulation, vol.139, issue.22, pp.2516-2527, 2019.

D. Fitchett, S. E. Inzucchi, C. P. Cannon, D. K. Mcguire, B. M. Scirica et al., Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial, Circulation, vol.139, issue.11, pp.1384-1395, 2019.

E. T. Kato, M. G. Silverman, O. Mosenzon, T. A. Zelniker, A. Cahn et al., Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus, Circulation, vol.139, issue.22, pp.2528-2536, 2019.

D. Fitchett, B. Zinman, C. Wanner, J. M. Lachin, S. Hantel et al., Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial, European Heart Journal, vol.37, issue.19, pp.1526-1534, 2016.

J. Butler and S. D. Anker, The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure, Circulation, vol.136, issue.16, pp.1459-1461, 2017.

J. J. Mcmurray, S. D. Solomon, S. E. Inzucchi, L. Køber, M. N. Kosiborod et al., Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, New England Journal of Medicine, vol.381, issue.21, pp.1995-2008, 2019.

M. Packer, S. D. Anker, J. Butler, G. Filippatos, S. J. Pocock et al., Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, New England Journal of Medicine, vol.383, issue.15, pp.1413-1424, 2020.

F. Zannad, J. P. Ferreira, S. J. Pocock, S. D. Anker, J. Butler et al., SGLT2 inhibitors in heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, pp.31824-31833, 2020.